Regulation of inflammatory responses by activated protein C: The molecular mechanism(s) and therapeutic implications

Clinical Chemistry and Laboratory Medicine

Volumn 42, Issue 2, 2004, Pages 132-141

  Okajima, Kenji ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Activated protein C; Disseminated intravascular coagulation; Endothelial cell injury; Neutrophils; Sepsis; Tumor necrosis factor

Indexed keywords

3 ACETOXYMETHYL 2 (2 CARBOXY 1 PYRROLIDINYLCARBONYL) 7ALPHA METHOXY 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 5,5 DIOXIDE; ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CELL RECEPTOR; ELASTASE INHIBITOR; ENDOTOXIN; GABEXATE MESILATE; HEPARIN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN S; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; STEROID; THROMBIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; BLEEDING TENDENCY; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; CELL SURFACE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; HUMAN; HYPOTENSION; IN VITRO STUDY; KIDNEY INJURY; LUNG BLOOD VESSEL; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SEPTIC SHOCK; SPINAL CORD INJURY;

ANIMALS; ANTICOAGULANTS; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; MONOCYTES; NF-KAPPA B; PROTEIN C; RATS; THROMBOMODULIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642566547     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2004.025     Document Type: Review

References (87)

1. Esmon CT. The protein C anticoagulant pathway. Arterioscl Thromb Vas 1992;12:135-45.
2. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994;269:26486-91.
3. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001;184:258-74.
4. Taylor FB Jr, Chang A, Esmon CT, D'Angelo A, ViganoD'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987;79:918-25.
5. Taylor FB Jr, Chang AC, Peer GT, Mather T, Blick K, Catlett R, et al. DEGR-F.Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood 1991;8:364-68.
6. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
7. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;28:1471-7.
8. St.John RC, Dorinsky PM. Immunologic therapy for ARDS, septic shock and multiple organ failure. Chest 1993;103:932-43.
9. Westlin WF, Gimbrone MA Jr. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol 1993;142:117-28.
10. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990;50:537-44.
11. Okajima K, Uchiba M. The anti-inflammatory properties of antithrombin III - new therapeutic implications. Semin Thromb Hemost 1998;24:27-32.
12. Ferrari-Baliviera E, Mealy K, Smith RJ, Wilmore DW. Tumor necrosis factor induces adult respiratory distress syndrome in rats. Arch Surg 1989;124:1400-5.
13. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Endotoxin-induced pulmonary vascular injury is mainly mediated by activated neutrophils in rats. Thromb Res 1995;78:117-25.
14. Murakami K, Okajima K, Uchiba M, Okabe H, Takatsuki K. Gabexate mesilate, a synthetic protease inhibitor, attenuates endotoxin-induced pulmonary vascular injury by inhibiting tumor necrosis factor production by monocytes. Crit Care Med 1996;24:1047-53.
15. Dhainaut JF, Mira JP, Brunet F. Platelet-activating factor antagonists as therapeutic strategy in sepsis. Progr Clin Biol Res 1994;388:277-93.
16. Koltai M, Hosford D, Braquet P. Role of PAF and cytokines in microvascular tissue injury. J Lab Clin Med 1992;119:461-6.
17. Chang SW, Feddersen CO, Hensosn PM, Voelkel NF. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987;79:1498-509.
18. Murakami K, Okajima K, Uchiba M, Johno M, Okabe H, Takatsuki K. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemost 1996;75:965-70.
19. Wachtfogel YT, Kucich U, James HL, Scott CF, Schapira M, Zimmerman M, et al. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J Clin Invest 1983;72:1672-7.
20. Wachtfogel YT, Pixley RA, Kucich U, Abrams W, Weinbaum G, Schapira M, et al. Purified plasma factor XIIa aggregates human neutrophils and causes degranulation. Blood 1986;67:1731-7.
21. Uchiba M, Okajima K, Murakami K, Okabe H, Okamoto S, Okada Y. Effects of plasma kallikrein specific inhibitor and active-site blocked factor VIIa on the pulmonary vascular injury induced by endotoxin in rats. Thromb Haemost 1997;78:209-14.
22. Moore FD Jr. Therapeutic regulation of the complement system in acute injury state. Adv Immunol 1994;56:267-99.
23. Rabinovici R, Yeh CG, Hillegass LM, Griswold DE, Di Martino MJ, Vernick JE, et al. Role of complement in endotoxin/platelet-activating factor-induced lung injury. J Immunol 1992;149:1744-50.
24. Uchiba M, Okajima K, Abe H, Okabe H, Takatsuki K. Effect of nafamostat mesilate on the activity of extrinsic pathway of coagulation. Thromb Res 1994;74:155-61.
25. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Inhibition of tissue-F.Vlla complex by nafamostat mesilate; a reply to the rebuttal. Thromb Res 1995;77:381-2.
26. Okajima K, Uchiba M, Murakami K. Nafamostat mesilate. Cardiovasc Drug Rev 1995;13:51-65.
27. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med 1997;155:711-8.
28. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996;87:642-7.
29. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997;272:L197-L202.
30. Bone RC. The pathogenesis of sepsis. Ann Int Med 1991;115:457-69.
31. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-64.
32. Szabo C, Mitchell JA, Thirmermann C. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock. Br J Pharmacol 1993;108:786-92.
33. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: Regulation and mechanism of action. Biochim Biophys Acta 1993;1178:153-75.
34. Thiemermann C. The role of the L-arginine: nitric oxide pathway in circulatory shock. Adv Pharmacol 1994;28:45-79.
35. Schulz R, Nava E, Moncada S. Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992;105:575-80.
36. Drapier JC, Wietzerbin J, Hibbs JB Jr. Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 1988;18:1587-92.
37. Mathison JC, Wolfson E, Ulevitch RJ. Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. J Clin Invest 1988;81:1925-37.
38. Isobe H, Okajima K, Uchiba M, Mizutani A, Harada N, Nagasaki A, et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001;104:1171-5.
39. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996;334:1448-60.
40. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Romos JC, et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996;97:1056-63.
41. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. J Clin Invest 1997;99:1165-72.
42. Losonczy G Jr. Early postischaemic renal fibrin deposition and reduction of glomerular filtration rate in the rat: Effect of the defibrinating agent Arwin. Acta Physiol Hung 1985;66:183-7.
43. Druid H, Enestrom S, Rammer L. Effect of anticoagulation upon nephron obstruction in experimental acute ischaemic renal failure. A morphological study. Int J Exp Path 1998;79:55-66.
44. Inauen W, Granger DN, Meininger CJ, Schelling ME, Granger HJ, Kvietys PR. An in vitro model of ischemia/reperfusion-induced microvascular injury. Am J Physiol 1990;259:G134-G139.
45. Bonventre JV, Colvin RB. Adhesion molecules in renal disease. Curr Opin Nephrol Hypertens 1996;5:254-61.
46. Liu W, Okajima K, Murakami K, Harada N, Isobe H, Irie T. Role of neutrophil elastase in stress-induced gastric mucosal injury in rats. J Lab Clin Med 1998;132:432-9.
47. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000;95:3781-7.
48. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994;330:377-81.
49. Liu W, Okajima K, Murakami K, Harada N, Isobe H, Irie T. Role of neutrophil elastase in stress-induced gastric mucosal injury in rats. J Lab Clin Med 1998;132:432-9.
50. Robert A. Cytoprotection by prostaglandins. Gastroenterology 1979;77:761-7.
51. 2) in chloralose anesthetized dogs. Br J Pharmacol 1977;61:136P.
52. Tateson JE, Moncada S, Vane JR. Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 1977;13:389-97.
53. 2 on gastric mucosal damage induced by stress, indomethacin and ethanol. Prostaglandins Leukot Essent Fatty Acids 1990;40:13-6.
54. Harada N, Okajima K, Liu W, Uchiba M. Activated neutrophils impair gastric cytoprotection role of neutrophil elastase. Dig Dis Sci 2000;45:1210-6.
55. Klebanoff SJ, Vadas MA, Harlan JM, Sparks LH, Gamble JR, Agosti JM, et al. Stimulation of neutrophils by tumor necrosis factor. J Immunol 1986;136:4220-5.
56. Isobe H, Okajima K, Harada N, Liu W, Okabe H. Activated protein C reduces stress-induced gastric mucosal injury in rats inhibiting the endothelial cell injury. J Thromb Haemost 2003.
57. White B, Schmidt K, Murphy C, Livingstone W, O'Toole D, Lawler M, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor κB (NFκB) and tumor necrosis factor α (TNF-α) production in the THP-1 monocytic cell line. Br J Haematol 2000;110:130-4.
58. Schmidt-Supprian M, Murphy C, White B, Lawler M, Kapurniotu A, Voelter W, et al. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur Cytokine Netw 2000;11:407-13.
59. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Ann Rev Immunol 1996;14:649-81.
60. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu Rev Immunol 2000;18:621-63.
61. Finco TS, Baldwin AS. Mechanistic aspects of NF-κB regulation: The emerging role of phosphorylation and proteolysis. Immunity 1995;3:263-72.
62. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-incluced tumor necrosis factor - a production by inhibiting activation of both nuclear factor-κB and activator protein-1 in human monocytes. Thromb Haemost 2002;88:267-73.
63. Conway EM, Van de Wouwer M, Pollefeyt S, Jurk K, Van Aken H, De Vriese A, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor κB and mitogen-activated protein kinase pathways. J Exp Med 2002;196:565-77.
64. Carlos TM, Harlan JM. Leukocyte-endothelial adhesion molecules. Blood 1994;84:2068-101.
65. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-203.
66. Taylor Jr FB, Steams-Kurosawa DJ, Kurosawa S, Ferrell G, Chang ACK, Laszik Z, et al. The endothelial cell protein C receptor aids in host defence against Escherichia coli sepsis. Blood 2000;95:1680-6.
67. Esmon CT. Role of coagulation inhibitors in inflammation. Thromb Haemost 2001;86:51-6.
68. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000;83:639-43.
69. Kurosawa S, Stearns-Kurosawa DJ, Carson CW, D'Angelo A, Della Valle P, Esmon CT. Plasma levels of endothelial cell protein C receptor are elevated in patients with sepsis and systemic lupus erythematosus: lack of correlation with thrombomodulin suggests involvement of different pathological process. Blood 1998;91:725-7.
70. Kurosawa S, Esmon CT, Sterans-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol 2000;165:4697-703.
71. Okajima K, Koga S, Kaji M, Inoue M, Okabe H, Takatsuki K, et al. Effects of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost 1989;63:48-53.
72. Okajima K, Imamura H, Koga S, Inoue M, Takatsuki K, Aoki N. Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 1990;33:277-8.
73. Okajima K, and the APC-IM Clinical Research Group in Japan. Treatment by activated protein C of patients with intravascular coagulation: Double-blind trial with heparin. Blood 2000;96:50a.
74. Ely WE, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003;31:12-9.
75. Opal SM, Cross AS. Clinical trials for severe sepsis. Infectious Disease Clinics of North America 1999;13:285-97.
76. Esmon CT. The normal role of activated protein C in maintaining homeostasis and its relevance to critical illness. Crit Care 2001;5:SUppl 2:S7-S12.
77. Okajima K, Harada N, Kushimoto S, Uchiba M. Role of microthrombus formation in the development of ischemia/reperfusion-induced liver injury in rats. Thromb Haemost 2002;88:473-80.
78. Okajima K, Harada N, Uchiba M. Microthrombus formation enhances tumor necrosis factor-a production in the development of ischemia/reperfusion-induced liver injury in rats. J Thromb Haemost 2003;1:1316-7.
79. Taoka Y, Okajima K. Spinal cord injury in the rat. Prog Neurobiol 1998;56:341-58.
80. Taoka Y, Okajima K. Role of leukocytes in spinal cord injury in rats. J Neurotrauma 2000;17:219-29.
81. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, et al. Gabexate mesilate, a synthetic protease inhibitor, prevents compression-induced spinal cord injury by inhibiting activation of leukocytes in rats. Crit Care Med 1997;25:874-9.
82. Taoka Y, Okajima K, Uchiba M, Murakami K, Kushimoto S, Johno M, et al. Role of neutrophils in spinal cord injury in the rat. Neuroscience 1997;79:1177-82.
83. Zimmerman BJ, Granger DH. Reperfusion-induced leukocyte infiltration role of neutrophil elastase. Am J Physiol 1990;259:H390-94.
84. Taoka Y, Okajima K, Johno M, Naruo M. Role of neutrophil elastase in compression-induced spinal cord injury in rats. Brain Res 1998;799:264-9.
85. Taoka Y, Okajima K, Uchiba M, Murakami K, Harada N, Johno M, et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting leukocyte activation. J Neurosci 1998;18:1393-8.
86. Lincott P, Hafez HM, Stansby G. Spinal cord complications of thrachoabdominal aneurysm surgery. Br J Surg 1998;85:5-15.
87. Hirose K, Okajima K, Taoka Y, Uchiba M, Tagami H, Nakano K, et al. Activated protein C reduces the ischemia-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg 2000;232:272-80.